Par announced the launch of Amlodipine and Valsartan Tablets, the generic version of Novartis’ Exforge. The Food and Drug Administration (FDA) granted final approval for its Abbreviated New Drug Application (ANDA) and has granted 180 days of marketing exclusivity.
Exforge contains amlodipine, a calcium channel blocker, and valsartan, an angiotensin II receptor blocker. Amlodipine and Valsartan Tablets are indicated for the treatment of hypertension, to lower blood pressure in patients inadequately controlled on monotherapy and as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
Amlodipine and Valsartan Tablets are available in 5mg/160mg, 10mg/160mg, 5mg/320mg, and 10mg/320mg strengths. Par has begun shipment of this product.
For more information call (800) 828-9393 or visit ParPharm.com.